People exposed to proton-pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: A nationwide matched cohort study.

Published in: British journal of clinical pharmacology (2022)

Premorbid exposure to PPIs does not affect the risk of death or hospitalization in adult COVID-19 patients, but PPI-requiring morbidities seemingly slightly increase the risk of both.

Keyphrases

sars cov
coronavirus disease
cardiovascular events
respiratory syndrome coronavirus
protein protein
cross sectional
childhood cancer
cardiovascular disease
young adults